Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed / refractory multiple myeloma by Ryan T. Bishop, Tao Li, Praneeth Sudalagunta, Mostafa Nasr, Karl J. Nyman, Raghunandan R. Alugubelli, Mark Meads, Jeremy Frieling, Niveditha Nerlakanti, Marilena Tauro, Bin Fang, Steven Grant, John Koomen, Ariosto S. Silva, Kenneth H. Shain, Conor C. Lynch

Get full text